Pasar al contenido principal

INVESTIGACION COMPARATIVA DE LA EFECTIVIDAD PARA LA TOMA DE DECISIONES COMPARTIDA EN EL TRATAMIENTO DEL CANCER DE PROSTATA LOCALIZADO CON MODALIDADES NUEVAS Y TRADICIONALES.

PI21/00023

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (FIMIM)
Centro realización INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (IMIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Economic Evaluation of Traditional Treatments for Localized Prostate Cancer, A 10-Year Cohort Study

  • Zamora, Víctor|||0000-0003-2061-0052
  • Bosch, Guillermo
  • Becerra, Virginia|||0000-0002-8811-3899
  • Garin, Olatz|||0000-0001-6193-0779
  • Ávila, Mónica|||0000-0001-9583-5104
  • Gutiérrez Miguélez, Cristina|||0000-0002-6944-772X
  • Suárez, José Francisco|||0000-0001-6427-4391
  • Goñi, Alai|||0000-0002-6365-9617
  • Macías Hernández, Víctor|||0000-0003-2904-5715
  • Mariño, Alfonso|||0000-0002-6720-3916
  • Hervás Morón, Asunción|||0000-0002-7439-1820
  • Herruzo, I.
  • Cabrera, Patricia|||0000-0001-6050-7354
  • Ponce de León Roca, Javier|||0000-0003-0250-2533
  • Sancho-Pardo, Gemma|||0000-0003-2266-6172
  • Pont, À.
  • Rubio-Valera, M.
  • Alonso, Jordi|||0000-0001-8627-9636
  • Cots Reguant, Francesc|||0000-0003-0238-8902
  • Guedea, Ferran|||0000-0001-8798-8696
  • Castells-Esteve, Manel|||0000-0003-2370-2008
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Objectives: To perform a cost-effectiveness analysis based on primary data from a cohort of patients with localized prostate cancer followed throughout 10 years, comparing radical prostatectomy, brachytherapy, and external beam radiotherapy (EBRT) and applying disease-specific utilities, from a national health system's perspective. Materials and Methods: Patients diagnosed with localized prostate cancer were consecutively recruited in 2003-2005 from 10 Spanish hospitals (n = 674) (ClinicalTrials.gov number: NCT01492751). The expanded prostate cancer index composite (EPIC) and short-form 36 (SF-36) questionnaires were administered through telephone interviews before treatment and annually during follow-up. The outcome measures to evaluate the incremental cost-effectiveness ratio between treatments (ICER) were quality-adjusted life-years (QALYs), calculated by the patient-oriented prostate utility scale (PORPUS) utility index, obtained with a mapping from the EPIC and the SF-36, and survival data. Ten-year medical activities were used to derive costs. Both unweighted and propensity score-weighted analyses were performed. Results: The weighted mean of 10-year QALYs was the highest for radical prostatectomy (8.53), followed by brachytherapy (8.49) and external radiotherapy (8.20), but the difference was only statistically significant with the latter. Costs were significantly higher for brachytherapy (€21,348) than radical prostatectomy (€12,281) and EBRT (€7,560). Compared to EBRT, the weighted ICER for radical prostatectomy was €14,169/QALY gained and €48,417/QALY for brachytherapy. Conclusion: Our findings support that radical prostatectomy was the most cost-effective alternative, but the differences in effectiveness among the three treatments were small. The incremental cost of radical prostatectomy and brachytherapy compared to EBRT, however, does not justify restricting these alternatives. Trial Registration: ClinicalTrials.gov identifier: NCT01492751.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Twenty-year Patient-reported Outcomes After Surgery, Radiotherapy, or Brachytherapy for Localized Prostate Cancer

  • Zamora, Víctor|||0000-0003-2061-0052
  • Garin, Olatz|||0000-0001-6193-0779
  • Suárez, José Francisco|||0000-0001-6427-4391
  • Guedea, Ferran|||0000-0001-8798-8696
  • Pont, Angels|||0000-0002-0602-552X
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Goñi, Alai|||0000-0002-6365-9617
  • Mariño, Alfonso|||0000-0002-6720-3916
  • Hervás Morón, Asunción|||0000-0002-7439-1820
  • Herruzo, Ismael
  • Cabrera, Patricia|||0000-0001-6050-7354
  • Sancho-Pardo, Gemma|||0000-0003-2266-6172
  • Ponce de León Roca, Javier|||0000-0003-0250-2533
  • Macías Hernández, Víctor|||0000-0003-2904-5715
  • Gutiérrez, Cristina|||0000-0003-2626-1957
  • Castells, Manuel
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Our study presents new results over a period of 20 years after treatment for localized prostate cancer, including differences that are important for shared decision-making. The greatest urinary incontinence occurred after radical prostatectomy, and the least deterioration in sexual function occurred after brachytherapy. Our objective was to compare the impact of open radical prostatectomy (RP), external beam radiotherapy (EBRT), and brachytherapy in patients with localized prostate cancer via patient-reported outcome measures up to 20 yr after treatment. This was a prospective observational study (ClinicalTrials.gov ) of men with localized prostate cancer (clinical stage T1-T2, low or intermediate risk). The Expanded Prostate Cancer Index Composite (EPIC-26) and Short Form-36 (SF-36) questionnaires were centrally administered via telephone interviews before treatment and then annually after treatment. Generalized estimating equation models were constructed with propensity score-based weights. The RP group reported gradual, statistically significant worsening for almost all EPIC-26 and SF-36 scores at most follow-up time points. Significantly lower urinary incontinence deterioration was observed in both radiotherapy groups than after RP. Urinary irritative/obstructive, sexual, bowel, and hormonal symptom patterns were similar regardless of treatment, except for less sexual deterioration in the brachytherapy group. The observational design is the main limitation, but propensity score weights mitigated treatment selection bias. Our findings provide detailed novel evidence, measured over 20 yr, on the long-term impact of disease and treatment on patients with localized prostate cancer. While all treatment groups showed a general deterioration over time, important differences in urinary incontinence (highest after RP) and sexual decline (least after brachytherapy) persisted at 20 yr, and these should be incorporated into shared decision-making processes. Our study provides new findings on outcomes of treatment for localized prostate cancer as reported by patients over a period of up to 20 years. There was a general deterioration over time, but worse urinary incontinence after radical prostatectomy and the lowest decline in sexual function after brachytherapy persisted over time. These findings can inform patients during shared decision-making on the most suitable treatment for localized prostate cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer, a 10-year follow-up cohort study

  • Suárez, José Francisco|||0000-0001-6427-4391
  • Zamora, Víctor|||0000-0003-2061-0052
  • Garin, Olatz|||0000-0001-6193-0779
  • Gutiérrez, Cristina|||0000-0003-2626-1957
  • Pont, Angels|||0000-0002-0602-552X
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Goñi, Alai|||0000-0002-6365-9617
  • Mariño, Alfonso|||0000-0002-6720-3916
  • Hervás, Asunción
  • Herruzo, Ismael
  • Cabrera, Patricia|||0000-0001-6050-7354
  • Sancho-Pardo, Gemma|||0000-0003-2266-6172
  • Ponce de León Roca, Javier|||0000-0003-0250-2533
  • Macías Hernández, Víctor|||0000-0003-2904-5715
  • Guedea, Ferran|||0000-0001-8798-8696
  • Vigués, Francesc|||0000-0003-3717-6301
  • Castells-Esteve, Manel|||0000-0003-2370-2008
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
To compare the effectiveness at ten years of follow-up of radical prostatectomy, brachytherapy and external radiotherapy, in terms of overall survival, prostate cancer-specific mortality and biochemical recurrence. Cohort of men diagnosed with localized prostate cancer (T1/T2 and low/intermediate risk) from ten Spanish hospitals, followed for 10 years. The treatment selection was decided jointly by patients and physicians. Of 704 participants, 192 were treated with open radical retropubic prostatectomy, 317 with 125 I brachytherapy alone, and 195 with 3D external beam radiation. We evaluated overall survival, prostate cancer-specific mortality, and biochemical recurrence. Kaplan-Meier estimators were plotted, and Cox proportional-hazards regression models were constructed to estimate hazard ratios (HR), adjusted by propensity scores. Of the 704 participants, 542 patients were alive ten years after treatment, and a total of 13 patients have been lost during follow-up. After adjusting by propensity score and Gleason score, brachytherapy and external radiotherapy were not associated with decreased 10-year overall survival (aHR = 1.36, p = 0.292 and aHR = 1.44, p = 0.222), but presented higher biochemical recurrence (aHR = 1.93, p = 0.004 and aHR = 2.56, p < 0.001) than radical prostatectomy at ten years of follow-up. Higher prostate cancer-specific mortality was also observed in external radiotherapy (aHR = 9.37, p = 0.015). Novel long-term results are provided on the effectiveness of brachytherapy to control localized prostate cancer ten years after treatment, compared to radical prostatectomy and external radiotherapy, presenting high overall survival, similarly to radical prostatectomy, but higher risk of biochemical progression. These findings provide valuable information to facilitate shared clinical decision-making. Study identifier at ClinicalTrials.gov : NCT01492751.